Review Highlights Urgency for New Lupus Nephritis Research

May 13, 2020

Outcomes for patients with lupus nephritis, which can lead to irreversible renal impairment, can be improved with better measures to evaluate risk and detect early disease, along with new treatments, say researchers writing in Nature Reviews Rheumatology.

Hydroxychloroquine Not Recommended for COVID-19 by NIH

April 23, 2020

This week, the National Institutes of Health issued treatment guidelines for the management of COVID-19. It does not include the use of pharmaceutical agents for pre or post-exposure prophylaxis, including hydroxychloroquine, except for within the confines of a clinical trial. This comes as good news to the rheumatology community. More in this article.

Image IQ: Erythema on Nose, Cheeks, Upper Back

April 02, 2020

A 16-year-old African American girl reports sudden erythema covering her nose, cheeks, and upper back. Can you diagnose this patient?

Hydroxychloroquine Production Surges for COVID-19

March 31, 2020

The rheumatology community has expressed concerns about the use of hydroxychloroquine sulfate for COVID-19 because the drug is used to treat lupus patients and is already in short supply. The FDA has taken steps to redistribute the drug to hospitals for COVID-19 patients despite the lack of extensive clinical trials testing.

SLE Patients Stake a Claim on Hydroxychloroquine

March 27, 2020

Patients with systemic lupus erythematosus depend on hydroxychloroquine to control disease activity, but demand for this drug, which was already in short supply, has spiked since President Trump championed its use for COVID-19 patients. The American College of Rheumatology has responded by issuing a series of recommendations. Learn more in this article.

The skinny on excess adipose and more in today's news roundup

February 14, 2020

Visceral fat appears to be associated with an increased risk of musculoskeletal and widespread pain, according to researchers writing this week in Arthritis and Rheumatology. Plus, a small study shows promise in a new treatment for a rare form of pediatric lupus. This and more news in today's rheumatology news roundup.

Anifrolumab Shows Efficiency in Systemic Lupus

January 28, 2020

In patients with moderate to severe systemic lupus erythematosus (SLE), anifrolumab (AstraZeneca) was superior to placebo for improving overall disease activity, skin disease and oral corticosteroid tapering, say researchers writing in the New England Journal of Medicine.

Lupus Trial for Anifrolumab Gets a Second Look

January 24, 2020

Anifrolumab, a potential new treatment for systemic lupus erythematosus (SLE), was given a second look in a clinical trial published in the New England Journal of Medicine this month. This time, the results look promising. Learn more about the trial in this slideshow.

Turning Points in Research for Systemic Lupus in 2019

December 24, 2019

In this slideshow, we feature the lupus stories that resonated most with our readers in 2019:  Lupus patients are increasingly turning to opioid use to control pain, a study that shows anifrolumab may be the next belimumab for lupus, patients are turning to pill splitting to keep costs down, among others.

Opioid Use in Systemic Lupus Erythematosus is on the Rise

December 20, 2019

Nearly one third of patients with systemic lupus erythematosus use prescription opioids, with around two thirds of those using opioids for more than a year, while emergency department use is associated with increased prescription opioid use, say researchers writing in Morbidity and Mortality Weekly Report in Septmeber.